A Repeat Dose, Open Label, Two Period, Randomized, Cross Over Study to Compare the Effect of Daprodustat to Recombinant, Human Erythropoietin (rhEPO) on Oral Iron Absorption in Adult Participants With Anemia Associated With Chronic Kidney Disease Who Are Not on Dialysis
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Daprodustat (Primary) ; Darbepoetin alfa; Epoetin alfa; Ferrous sulfate; Recombinant erythropoietin
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 18 Nov 2019 Planned End Date changed from 24 Feb 2020 to 22 May 2020.
- 18 Nov 2019 Planned primary completion date changed from 24 Feb 2020 to 22 May 2020.
- 13 Aug 2019 Status changed from not yet recruiting to recruiting.